Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Aventis Divests Azmacort For $200 Mil.; Kos To Back Relaunch With 500 Reps

Mar 15 2004

• By The Pink Sheet

Related Content

FDA 2004 Reg Agenda Includes CFC Albuterol Phase Out, Final Label Rule

Jan 05 2004

Aventis Defense Against Sanofi: Strong Pipeline Or Irrational “Exubera-nce”?

Feb 09 2004

Hoechst Marion Roussel's Arava Posts $21 Mil. In 1998 U.S. Sales

Mar 22 1999

Rhone-Poulenc Rorer Azmacort HFA

Jun 07 1999

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window